BERYWN, Pa., Aug. 16 /PRNewswire/ -- DermAvance Pharmaceuticals, a
privately held pharmaceutical company specializing in advanced technology
applications for skin health and cosmetic dermatology, today announced the
acquisition of the North American rights for the Hyalogy(TM) Total Skin
Care Line from Forlle'd in Japan.
Hyalogy(TM) P-effect represents a novel breakthrough formulation
technology, using a proprietary nanotechnology process, to create the first
product for the cosmeceutical market that allows topically applied
hyaluronic acid to penetrate the skin's epidermal barrier. The Hyalogy(TM)
Total Skin Care Line is designed to provide deep hydration into the skin
more effectively and for a prolonged period of time over current
formulations of traditional skin moisturizers.
The amount of moisture in skin, a source of youth and beauty, decreases
with age. Hyaluronic acid, a naturally occurring substance produced by the
body, is what gives skin its volume and fullness. Adults have only 1/20th
of the amount of hyaluronic acid as a baby. Until now, hyaluronic acid had
to be injected into the dermis because earlier formulations were not able
to penetrate the skin topically. With extensive research efforts, using
advanced infiltration nanotechnology, an ultra low molecular weight
hyaluronic acid with superior ability to penetrate through to the deep
layers of the skin has been created. Hyalogy(TM) P-effect conveys the
extraordinary function of hyaluronic acid and delivers moisture deep
beneath the skin surface without the use of needles. "The unique advantage
of Hyalogy(TM) P-effect is its ability to penetrate deep beneath the skin's
epidermal barrier," said W. Philip Werschler, MD/FAAD, board certified
dermatologist and Assistant Clinical Professor at the University Of
Washington School Of Medicine.
"The introduction of cosmeceutical nanotechnology will not only
significantly effect cosmeceutical formulations but may very well
revolutionize drug delivery systems in a number of key areas," commented
Keith Greathouse, President and CEO of DermAvance. "We are very excited
about our collaboration with Forlle'd, who is at the forefront of
nanotechnology development in cosmetic dermatology and innovative
cosmeceutical formulations. We expect to launch the Hyalogy(TM) Total Skin
Care Line early in the 4th Quarter of 2006."
About DermAvance Pharmaceuticals, Inc.
DermAvance Pharmaceuticals, Inc. is a privately held dermatology
pharmaceutical company focused on commercializing unique, and innovative
anti- aging products to enhance the health and appearance of skin. The
company was founded to meet the rapidly growing demand for facial skin
rejuvenation products. DermAvance expects to launch several unique product
lines in the 4th Quarter of 2006, including Vivelif(R) (acetyl
hexapeptide-3), an innovative topical peptide preparation designed to
reduce the visible signs of aging by targeting biochemical mechanisms of
wrinkle formation similar to the activity of neurotoxins. DermAvance
markets and sells products directly to dermatologists and aesthetic
physicians for in-office dispensing.
For additional information contact:
Kathleen Sugg (610) 727-3959 Keith Greathouse (610) 727-4066
Vice President of Marketing President & CEO
SOURCE DermAvance Pharmaceuticals, Inc.